




Abstract—The authors used 1H-MRS to investigate hypothalamic metabolism
in 26 patients with cluster headache (CH) and 12 healthy subjects. Hypotha-
lamic N-acetylaspartate/creatine was reduced in patients with CH vs controls
(p  0.01). Dividing the patients into episodic CH outside- and in-cluster
periods and chronic CH, the hypothalamic N-acetylaspartate/creatine in all
three subgroups of patients was reduced. The reduction of the neuronal marker
N-acetylaspartate is consistent with hypothalamic neuronal dysfunction in
patients with CH.
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Cluster headache (CH) is characterized by severe
unilateral orbital, supraorbital, and/or temporal pain
associated with cranial ipsilateral parasympathetic
activation and sympathetic deficit. Attacks last from
15 to 180 minutes, and there can be as many as eight
per day. In episodic CH, attacks occur in clusters
lasting 7 to 365 days separated by pain-free periods
of 1 month. In chronic CH, affecting one-fifth of
patients, attacks recur over 1 year without remis-
sion periods or with remission periods lasting 1
month.1
The striking circadian rhythmicity of CH attacks
has pointed to the hypothalamus as a strong candi-
date site for triggering the attack. Functional neuro-
imaging studies performed using PET in patients
with chronic CH during nitroglycerin-induced at-
tacks showed increased blood flow in the ipsilateral
hypothalamic gray matter.2 Using a voxel-based
morphometric (VBM) analysis of MRI, structural dif-
ferences in gray matter density consistent with an
increased volume have been detected bilaterally in
the hypothalamus of patients with CH either in or
outside a cluster.3
Proton MR spectroscopy (1H-MRS) allows the non-
invasive and spatially resolved measurement of sev-
eral brain compounds including N-acetylaspartate
(NAA), a neuronal marker that is reduced when neu-
ronal dysfunction or loss occurs. In this study, we
used 1H-MRS to investigate whether biochemical ab-
normalities consistent with functional or structural
changes are present in the hypothalamus of patients
with CH.
Methods. Twenty-six patients with CH (aged 26 to 67 years; 24
men and two women) (table) and 12 healthy controls (26 to 65
years; 11 men and one woman) were recruited. According to the
International Classification of Headache Disorders II criteria1 18
patients had episodic CH and eight had the chronic form. Among
the patients with episodic CH, eight were scanned outside and
ten, all pain-free, within the cluster.
1H-MRS studies were performed in a 1.5-T GE scanner as
previously described.4 A volume of interest (VOI) ranging from 1
to 1.2 cm3 was selected to include bilateral hypothalamic gray
matter (figure 1). Spectra were acquired using the PRESS single
voxel sequence (TR  1500 msec; TE  144 msec; number of
acquisitions  1536). In 23 patients with CH and 11 healthy
controls, two additional spectra were acquired from the mid-line
parietal-occipital cortex and left parietal white matter (VOI  8
cm3) (TR  1500 msec; TE  40 msec; number of acquisitions 
128). Automatic shimming was used. Typically, the water line
width was around 5 to 7 Hz for hypothalamic VOIs, whereas a line
width of 3 to 4 Hz could be achieved in white matter and cortical
VOIs. The greater spectral resolution permitted the use of a short
echo time, giving a substantially increased signal-to-noise ratio for
a given scan duration, at the expense of more complex peak
quantitation.
Peak areas for NAA, creatine-phosphocreatine (Cr), and cho-
line (Cho) were calculated using the time domain fitting program
AMARES/MRUI. Peak integral values were expressed relative to
the Cr peak.
Significance, taken as p  0.05, was determined by the Stu-
dent t test for unpaired data when all patients with CH were
compared to controls, and Fisher’s protected least significant dif-
ference test (post hoc analysis of variance) when the three sub-
groups of patients with CH and controls were compared. Linear
regression analysis was used to calculate correlation coefficients.
Results. In patients with CH, hypothalamic NAA/Cr
(1.63  0.21) was reduced compared to controls (1.94 
0.27; p  0.0004) (figure 1), whereas Cho/Cr was similar in
patients with CH (1.85  0.33) and healthy controls (1.96
 0.26; p  0.3). In patients with CH, hypothalamic NAA/
Cho was also reduced (0.88  0.09 vs 0.99  0.12 in con-
trols; p  0.002). Dividing our patients into episodic CH
outside- (n  8) and in-cluster periods (n  10) and chronic
CH (n  8), the hypothalamic NAA/Cr in all three sub-
groups of patients was lower than in healthy controls:
1.65  0.22 (p  0.01) in patients outside-cluster, 1.61 
0.22 (p  0.002) in patients in-cluster, 1.64  0.22 (p 
0.008) in chronic CH (figure 2). Hypothalamic NAA/Cr did
not show statistical differences among the subgroups of
patients with CH. No statistical difference was found be-
tween hypothalamic Cho/Cr values in healthy controls and
the three subgroups of patients.
In patients with CH, the mean NAA/Cr in the parietal-
occipital cortex (1.37  0.14) and white matter (1.67 
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0.21) did not differ from that found in healthy volunteers
(cortical NAA/Cr  1.37  0.15, p  0.9; white matter
NAA/Cr  1.64  0.22, p  0.7). Similarly, in patients
with CH, the mean Cho/Cr in the cortex (0.70  0.08) and
white matter (1.12  0.16) did not differ from that found in
healthy volunteers (cortical Cho/Cr  0.66  0.10, p  0.3;
white matter Cho/Cr  1.09  0.11, p  0.6).
No correlations were found between 1H-MRS variables
and years from onset, cluster duration (for patients with
episodic CH in-cluster), interval from the end of the last
cluster (for patients with episodic CH out-cluster), and du-
ration of the chronic CH condition (for patients with
chronic CH).
Discussion. We demonstrated that the neuronal
marker NAA is reduced in the hypothalamus of pa-
tients with CH examined during an attack-free state.
NAA is found primarily in mature neurons and
neuronal processes and is therefore considered a
neuronal marker in mature human brains. De-
creased NAA content is observed in pathologic pro-
cesses in which neuronal loss occurs, such as
degenerative disorders, stroke, and glial tumors, but
also in the presence of neuronal dysfunction such as
temporal lobe epilepsy and multiple sclerosis, in
which therapeutic interventions may be associated
with an increase in NAA content.5,6 VBM-MRI dis-
closed an increase in hypothalamic gray matter vol-
ume in patients with CH.3 Abnormalities were
bilateral and were similar in patients examined dur-
ing active headache and in a headache-free state.3
VBM-MRI findings taken together with our 1H-
MRS results show that the hypothalamus of patients
with CH has an increased density of neurons associ-
ated with reduced NAA/Cr. A relative increase in
hypothalamic gray matter in patients with CH can
per se contribute to the observed reduced NAA/Cr as
NAA content is lower in gray than white matter.7
Reduced NAA content in a brain area where the
number of neurons is normal or, as possible in CH,
increased, could also suggest the presence of either
immature or dysfunctional neurons expressing less
NAA. This is the case, for example, in a brain area
with heterotopic gray matter where an increased
number of neurons that are normal-appearing and
with active synapses may show reduced NAA
content.8
In healthy subjects, a relationship has been found
between the brain concentration of NAA and adeno-
sine diphosphate,9 the major regulator of mitochon-
drial oxidative phosphorylation. As 31P-MRS
disclosed a bioenergetics deficit in the occipital
cortex of patients with CH,10 we investigated, by as-
Table Demographic and clinical data of patients with cluster
headache
Episodic CH patients:
out of cluster/case no.
Age, y/sex/age
at onset, y
Interval from the end of
last cluster-MRS, mo Therapy
1 45/M/26 1 None
2 34/M/27 1 None
3 55/M/46 9 None
4 52/M/33 9 None
5 49/M/17 14 None
6 42/M/24 14 None
7 39/M/29 12 None






at MRS, d Therapy
9 63/M/46 12 V
10 54/M/22 21 M
11 51/M/20 5 V, E
12 36/M/22 31 V, E
13 49/F/28 42 P, D
14 52/M/38 101 V
15 41/M/35 120 M, L
16 46/F/39 33 V, E
17 31/M/26 27 V, E







19* 42/M/40 24 V
20* 59/M/49 120 V, L
21 49/M/32 18 P, V, C
22* 47/M/44 36 V, M
23 37/M/18 18 P
24 48/M/36 104 E
25 36/M/34 18 L
26 26/M/15 24 V, D
* Cluster headache chronic at onset.
CH  cluster headache; MRS  MR spectroscopy; V  verapamil; M 
methysergide; E  ergotamine; P  prednisone; D  dihydroergotamine;
L lithium; C  clonidine.
Figure 1. (Left) Axial fast gradient echo
image showing hypothalamic voxel lo-
calization. Center and right: proton spec-
tra (TR  1500 msec; TE  144 msec)
from a healthy volunteer and a patient
with episodic cluster headache (CH) out-
side the cluster period. In the patient, the
N-acetylaspartate (NAA) peak is mark-
edly reduced compared to that of the
healthy volunteer. Cr  total creatine;
Cho  choline; ppm  part per million.
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sessing NAA levels in two extrahypothalamic hemi-
spheric VOIs, whether the reduced hypothalamic
NAA/Cr in CH could be related to a nonspecific re-
sult of a diffuse brain bioenergetics deficit. The de-
tection of normal levels of NAA/Cr in the cortex and
white matter of our patients with CH tends to ex-
clude that the reduction in hypothalamic NAA may
be secondary to a diffuse brain bioenergetics deficit.
Our study detected a reduced NAA/Cr in the hypo-
thalamus of patients with CH, a neurochemical ab-
normality consistent with both relative increase in
gray matter content and neuronal dysfunction. All
examined patients were in a headache-free state
during the 1H-MRS scan. This makes it unlikely that
the reduction in NAA/Cr is secondary to headache
attacks and activation of central pain mechanisms
per se. The finding that NAA/Cr is also reduced in
the group of patients with CH outside the cluster
period and free from therapy indicates that such al-
teration is a permanent feature of patients with CH.
Although the mechanism leading to hypothalamic
NAA/Cr reduction in patients with CH is not known,
low NAA/Cr may be an expression of neuronal hypo-
thalamic malfunction that combined with other fac-
tors triggers headache attacks.
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Figure 2. Hypothalamic N-acetylaspartate/creatine (NAA/
Cr) in healthy subjects, in patients with episodic cluster
headache (CH) out- and in-cluster periods, and in patients
with chronic CH. NAA/Cr was significantly reduced (Fish-
er’s protected least significant difference test) in the hypo-
thalamus of all subgroups of patients. Horizontal bars
indicate groups’ mean value.
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